The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
Publication
, Journal Article
Kircher, SM; Meeker, CR; Nimeiri, H; Geynisman, DM; Zafar, SY; Shankaran, V; de Souza, J; Wong, Y-N
Published in: Value Health
January 2016
Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Value Health
DOI
EISSN
1524-4733
Publication Date
January 2016
Volume
19
Issue
1
Start / End Page
88 / 98
Location
United States
Related Subject Headings
- United States
- Patient Protection and Affordable Care Act
- Insurance, Health
- Insurance Coverage
- Humans
- Health Policy & Services
- Health Expenditures
- Fees, Pharmaceutical
- Cost Sharing
- Antineoplastic Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Kircher, S. M., Meeker, C. R., Nimeiri, H., Geynisman, D. M., Zafar, S. Y., Shankaran, V., … Wong, Y.-N. (2016). The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications? Value Health, 19(1), 88–98. https://doi.org/10.1016/j.jval.2015.10.005
Kircher, Sheetal M., Caitlin R. Meeker, Halla Nimeiri, Daniel M. Geynisman, S Yousuf Zafar, Veena Shankaran, Jonas de Souza, and Yu-Ning Wong. “The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?” Value Health 19, no. 1 (January 2016): 88–98. https://doi.org/10.1016/j.jval.2015.10.005.
Kircher SM, Meeker CR, Nimeiri H, Geynisman DM, Zafar SY, Shankaran V, et al. The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications? Value Health. 2016 Jan;19(1):88–98.
Kircher, Sheetal M., et al. “The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?” Value Health, vol. 19, no. 1, Jan. 2016, pp. 88–98. Pubmed, doi:10.1016/j.jval.2015.10.005.
Kircher SM, Meeker CR, Nimeiri H, Geynisman DM, Zafar SY, Shankaran V, de Souza J, Wong Y-N. The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications? Value Health. 2016 Jan;19(1):88–98.
Published In
Value Health
DOI
EISSN
1524-4733
Publication Date
January 2016
Volume
19
Issue
1
Start / End Page
88 / 98
Location
United States
Related Subject Headings
- United States
- Patient Protection and Affordable Care Act
- Insurance, Health
- Insurance Coverage
- Humans
- Health Policy & Services
- Health Expenditures
- Fees, Pharmaceutical
- Cost Sharing
- Antineoplastic Agents